Guidelines

Guidelines BHS

2022

• BHS guidelines on supportive care in lymphoma: Part 2
• BHS guidelines on supportive care in lymphoma: Part 1
• Diagnosis and treatment of peripheral T-cell lymphomas: Update recommendations of the Belgian Hematology Society (BHS)

2021

• Guidelines of the Belgian Hematology Society for imaging in multiple myeloma
• How to treat classical Hodgkin’s lymphoma in older patients: Belgian expert opinion
• Management of polycythemia vera: Recommendations from the BHS MPN subcommittee anno 2021
• Primary immune thrombocytopenia in adults: Belgian recommendations for diagnosis and treatment anno 2021 made by the Belgian Hematology Society
• Belgian guidelines for diagnosis and treatment of chronic myelomonocytic leukaemia

2020

• Diagnosis and treatment of AL amyloidosis: Belgian guidelines
• Practical management of multiple myeloma: Update 2020
• BHS Guidelines for the Management of Small Lymphocytic Lymphoma and Chronic Lymphocytic Leukaemia, anno 2020
• BHS guidelines for the treatment of newly diagnosed diffuse large B-cell lymphoma (DLBCL) anno 2020

2019

• Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma anno 2019
• Diagnostic testing in myeloid malignancies by next-generation sequencing: recommendations from the Commission Personalised Medicine
• BHS guidelines for the treatment of marginal zone lymphomas: 2018 update
• BHS clinical guidelines on the management of acute complications in sickle cell disease
• Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases

2018

• Hodgkin’s lymphoma: Belgian Hematology Society guidelines in diagnosis, treatment and follow-up
• Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia, mantle cell lymphoma and Waldenström macroglobulinemia anno 2018

2016

• BHS guidelines for the treatment of large granular lymphocyte and chronic prolymphocytic leukaemias
• BHS guidelines for primary central nervous system lymphoma
• Updated BHS guidelines for the treatment of chronic lymphocytic leukaemia anno 2016

2015

• Diagnosis and treatment of AL Amyloidosis in 2015: Consensus guidelines of the Belgian Hematological Society
• Treatment of mantle cell lymphomas: Updated recommendations of the Belgian Hematological Society 2015
• Waldenström’s macroglobulinaemia: Belgian Hematology Society guidelines
• BHS 2013 recommendations for treatment of myelodysplastic syndromes
• BHS Guidelines for the treatment of Burkitt’s lymphoma
• The 2013 Belgian Hematological Society recommendations for the diagnosis and classification of myelodysplastic syndromes
• Practical management of chronic myeloid leukemia in Belgium

2014

• Update on the initial therapy of multiple myeloma
• Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society
• Vaccination guidelines in haematopoietic transplant patients: recommendations from the BHS Transplant Committee
• BHS guidelines for the treatment of marginal zone lymphomas

2013

• Disease characteristics in Belgian myelofibrosis patients and management guidelines anno 2013
• Guidelines for newly diagnosed diffuse large B-cell lymphoma (DLBCL) and relapsed DLBCL
• Primary immune thrombocytopenia in adults

2012

• BHS guidelines for the treatment of chronic lymphocytic leukaemia anno 2012
• Point of view about new guidelines on ESAs (erythropoiesis-stimulating agents)
• Guidelines of the Belgian Hematological Society for newly diagnosed and relapsed follicular lymphoma 2012

2011

• Use of alemtuzumab in B-cell chronic lymphocytic leukaemia: Belgian recommendations

2010

• Guidelines of the Belgian Hemovigilance Report